Our data above suggest that loss of WT KRAS in the context of an oncogenic KRASG12D mutant can facilitate early tumor initiation, in concordance with prior studies suggesting that under certain circumstances, WT KRAS can act as a tumor suppressor (31) and that loss of WT KRAS can drive progression (32). Here, KRAS is linked to neoplasm.